Fulcrum Therapeutics Reports Second Quarter 2019 Financial Results and Recent Business Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Fulcrum Therapeutics Inc. (FULC) Misses Q2 EPS by 611c
August 26, 2019 7:13 AM EDTFulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q2 EPS of ($9.21), $6.11 worse than the analyst estimate of ($3.10).
Second Quarter 2019 and Recent Business Highlights
In August 2019, Fulcrum announced that it initiated ReDUX4, its Phase 2b clinical trial evaluating losmapimod for the treatment of FSHD.In August 2019, Fulcrum announced that it initiated a Phase 2 open label clinical trial evaluating losmapimod for the treatment of FSHD.In July 2019, Fulcrum completed its initial public offering of common stock, raising $72.0 million in gross proceeds.Second Quarter 2019 Financial Results
Cash Position: As of June 30, 2019, cash and... More